IMP3 as a cytoplasmic biomarker for early serous tubal carcinogenesis

Journal of Experimental & Clinical Cancer Research

Wenxin Zheng²  Kenneth D Hatch²  Wenjing Zhang¹  Zeng Yuan¹  Yue Wang⁴  Lingmin Li³  Yiying Wang⁴ 

[1] Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan, China;Arizona Cancer Center, University of Arizona, Tucson, AZ;Department of Pathology, Shanxi Medical University, Taiyuan, China;Department of Pathology, University of Arizona College of Medicine, Tucson, AZ

关键词: High-grade serous carcinoma;    p53 signature;    STIC;    Serous tubal intraepithelial carcinoma;    IMP3;   

Others  :  1136184
DOI  :  10.1186/s13046-014-0060-2

 received in 2014-05-08, accepted in 2014-07-01,  发布年份 2014

【 摘 要 】

Background

Serous tubal intraepithelial carcinoma (STIC) and the p53 signature in tubal mucosa have been supported to be precursor lesions in high-grade serous carcinoma (HGSC) of the fallopian tube, ovary, and peritoneum. It remains critical to find biomarkers for precursor lesions in order to detect HGSCs efficiently. IMP3 is an oncoprotein that has been explored in human malignancies. No studies have specifically addressed the expression of IMP3 in precursor or early lesions of HGSC. The main purposes of this study are to evaluate if IMP3 plays any role in the process of pelvic serous carcinogenesis by examining its expression in HGSC precursor lesions, to examine the relationship between IMP3 and p53 in those precursor lesions, and to check if IMP3 can be used as a biomarker for early diagnosis.

Methods

Immunohistochemistry for IMP3 and p53 was performed and evaluated in 48 HGSCs with STIC, 62 HGSCs without STIC, and 60 benign cases as negative controls. Sections of fallopian tubes with or without STIC , as well as cancers within the ovaries, were studied. IMP3 signature was defined as strong IMP3 cytoplasmic staining in 10 or more consecutive benign-looking tubal epithelial cells. The relationship between IMP3 and p53 overexpression was examined.

Results

In the 48 HGSC patients with STIC, IMP3 was positive in 46% of STIC lesions and had a similar positive rate in the invasive components of HGSC. IMP3 was also expressed in normal appearing tubal epithelia (IMP3 signature) in 15 (31%) of 48 HGSC cases with STIC and 10 (16%) of 62 cases without STIC. In contrast, no single IMP3 signature was found in the benign control group. Concordant expression of IMP3 and p53 signatures in the STIC group was found in up to one-third of the cases. There were also five (10%) STIC cases with positive IMP3 and negative p53.

Conclusions

We conclude that IMP3 may be involved in the process and progression of pelvic HGSC and may serve as a complimentary biomarker in diagnosing STIC.

【 授权许可】

   
2014 Wang et al.; licensee BioMed Central Ltd

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Cannistra SA: Cancer of the ovary. N Engl J Med 1993, 329:1550-1559.
• [2]Delair D, Soslow RA: Key features of extrauterine pelvic serous tumours (fallopian tube, ovary, and peritoneum). Histopathology 2012, 61:329-339.
• [3]Li J, Fadare O, Xiang L, Kong B, Zheng W: Ovarian serous carcinoma: recent concepts on its origin and carcinogenesis. J Hematol Oncol 2012, 5:8. BioMed Central Full Text
• [4]Brewer MA, Johnson K, Follen M, Gershenson D, Bast R Jr: Prevention of ovarian cancer: intraepithelial neoplasia. Clin Cancer Res 2003, 9:20-30.
• [5]Callahan MJ, Crum CP, Medeiros F, Kindelberger DW, Elvin JA, Garber JE, Feltmate CM, Berkowitz RS, Muto MG: Primary Fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol 2007, 25:3985-3990.
• [6]Carlson JW, Miron A, Jarboe EA, Parast MM, Hirsch MS, Lee YH, Muto MG, Kindelberger D, Crum CP: Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2008, 26:4160-4165.
• [7]Crum CP: Intercepting pelvic cancer in the distal fallopian tube: Theories and realities. Mol Oncol 2009, 3:165-170.
• [8]Crum CP, Drapkin R, Miron A, Ince TA, Muto M, Kindelberger DW, Lee YH: The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gyn 2007, 19:3-9.
• [9]Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, Garder J, Birch C, Mou H, Gordon RW, Cramer DW, McKeon FD, Crum CP: A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 2007, 211:26-35.
• [10]Li J, Abushahin N, Pang S, Xiang L, Chambers SK, Fadare O, Kong B, Zheng W: Tubal origin of ‘ovarian’ low-grade serous carcinoma. Mod Pathol 2011, 24:1488-1499.
• [11]Quick CM, Ning G, Bijron J, Laury A, Wei TS, Chen EY, Vargas SO, Betensky RA, McKeon FD, Xian W, Crum CP: PAX2-null secretory cell outgrowths in the oviduct and their relationship to pelvic serous cancer. Mod Pathol 2012, 25:449-455.
• [12]Przybycin CG, Kurman RJ, Ronnett BM, Shih IM, Vang R: Are All Pelvic (Nonuterine) Serous Carcinomas of Tubal Origin? Am J Surg Pathol 2010, 34:1407-1416.
• [13]Rivlin N, Brosh R, Oren M, Rotter V: Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis. Genes Cancer 2011, 2:466-474.
• [14]Levanon K, Crum C, Drapkin R: New Insights Into the Pathogenesis of Serous Ovarian Cancer and Its Clinical Impact. J Clin Oncol 2008, 26:5284-5293.
• [15]Folkins AK, Jarboe EA, Saleemuddin A, Lee Y, Callahan MJ, Drapkin R, Garber JE, Muto MG, Tworoger S, Crum CP: A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol 2008, 109:168-173.
• [16]Kuhn E, Kurman RJ, Vang R, Sehdev AS, Han GM, Soslow R, Wang TL, Shih IM: TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma-evidence supporting the clonal relationship of the two lesions. J Pathol 2012, 226:421-426.
• [17]Mueller-Pillasch F, Lacher U, Wallrapp C, Micha A, Zimmerhackl F, Hameister H, Varga G, Friess H, Buchler M, Beger HG, Vila MR, Adler G, Gress TM: Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene 1997, 14:2729-2733.
• [18]Mueller-Pillasch F, Pohl B, Wilda M, Lacher U, Beil M, Wallrapp C, Hameister H, Knochel W, Adler G, Gress TM: Expression of the highly conserved RNA binding protein KOC in embryogenesis. Mech Dev 1999, 88:95-99.
• [19]Kobel M, Xu HD, Bourne PA, Spaulding BO, Shih IM, Mao TL, Soslow RA, Ewanowich CA, Kalloger SE, Mehl E, Lee CH, Huntsman D, Gilks CB: IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. Mod Pathol 2009, 22:469-475.
• [20]Yaniv K, Yisraeli JK: The involvement of a conserved family of RNA binding proteins in embryonic development and carcinogenesis. Gene 2002, 287:49-54.
• [21]Zheng W, Yi X, Fadare O, Liang SX, Martel M, Schwartz PE, Jiang Z: The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma. Am J Surg Pathol 2008, 32:304-315.
• [22]Lu D, Yang XF, Jiang NY, Woda BA, Liu Q, Dresser K, Mercurio AM, Rock KL, Jiang Z: IMP3, a New Biomarker to Predict Progression of Cervical Intraepithelial Neoplasia Into Invasive Cancer. Am J Surg Pathol 2011, 35:1638-1645.
• [23]Li CZ, Rock KL, Woda BA, Jiang Z, Fraire AE, Dresser K: IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: an immunohistochemical study in comparison with p16(INK4a) expression. Mod Pathol 2007, 20:242-247.
• [24]Findeis-Hosey JJ, Xu H: Insulin-like growth factor II-messenger RNA-binding protein-3 and lung cancer. Biotech Histochem 2012, 87:24-29.
• [25]Medeiros F, Muto MG, Lee Y, Elvin JA, Callahan MJ, Feltmate C, Garber JE, Cramer DW, Crum CP: The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 2006, 30:230-236.
• [26]Jarboe E, Folkins A, Nucci MR, Kindelberger D, Drapkin R, Miron A, Lee YH, Crum CP: Serous carcinogenesis in the fallopian tube: A descriptive classification. Int J Gynecol Pathol 2008, 27:1-9.
• [27]Jiang Z, Chu PGG, Woda BA, Rock KL, Liu Q, Hsieh CC, Li CZ, Chen WG, Duan HO, McDougal S, Wu CL: Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol 2006, 7:556-564.
• [28]Yantiss RK, Woda BA, Fanger GR, Kalos M, Whalen GF, Tada H, Andersen DK, Rock KL, Dresser K: KOC (K homology domain containing protein overexpressed in cancer) - A novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am J Surg Pathol 2005, 29:188-195.
• [29]Han LM, Linxuan W, Ferguson DC, Chambers SK, Oluwole F, Yiying W, Wenxin Z: From endometrial glandular dysplasia to endometrial serous carcinoma: insights into underlying biological aspects. Am J Clin Exp Obstet Gynecol 2013, 1:1-16.
• [30]Li J, Ning Y, Abushahin N, Yuan Z, Wang YY, Wang Y, Yuan BB, Cragun JM, Chambers SK, Hatch K, Kong BH, Zheng WX: Secretory cell expansion with aging: Risk for pelvic serous carcinogenesis. Gynecol Oncol 2013, 131:555-560.
• [31]Lee Y, Medeiros F, Kindelberger D, Callahan MJ, Muto MG, Crum CP: Advances in the recognition of tubal intraepithelial carcinoma - Applications to cancer screening and the pathogenesis of ovarian cancer. Adv Anat Pathol 2006, 13:1-7.
• [32]Zheng WX, Khurana R, Farahmand S, Wang YL, Zhang ZF, Felix JC: p53 immunostaining as a significant adjunct diagnostic method for uterine surface carcinoma - Precursor of uterine papillary serous carcinoma. Am J Surg Pathol 1998, 22:1463-1473.
• [33]Noske A, Faggad A, Wirtz R, Darb-Esfahani S, Sehouli J, Sinn B, Nielsen FC, Weichert W, Buckendahl AC, Roske A, Muller B, Dietel M, Denkert C: IMP3 Expression in Human Ovarian Cancer is Associated With Improved Survival. Int J Gynecol Pathol 2009, 28:203-210.
• [34]Kurman RJ, Shih IM: The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory. Am J Surg Pathol 2010, 34:433-443.